SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11086)3/28/2017 3:29:14 PM
From: tuck  Respond to of 12215
 
FWIW, the CMO did throw in a tidbit about the oral OA trial: that they were not seeing aquaresis in that one. Hopefully, that means we won't see the hypernatremia, either. They believe the hypernatremia was at least partly secondary to aquaresis in the early IV pain trials, so the lack of aquaresis in the oral OA trial is a good sign, at least.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News